CBER outlines future biologics, biosimilars plans

With greater development of biologic medications, biosimilars and companion diagnostics, the FDA Center for Biologics Evaluation and Research's role in health care is growing, speakers said at FDLI's annual meeting. CBER office directors discussed plans for the center, which include a push to publish the draft guidance Preclinical Safety Assessment of Investigational Cellular and Gene Therapy Products.

View Full Article in:

CBER Importance Boosted With Attention To Biologic Drugs, Biosimilars, Speakers Say - Bloomberg BNA

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA